Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 7/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 12/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL642085 | 0.93 | F2R (0.51) | F2RCNR1TMEM97EPHX2EPHX1 | |
| SCHEMBL641909 | 0.83 | F2R (0.54) | F2RCNR1TMEM97EPHX2 | |
| SCHEMBL642573 | 0.82 | F2R (0.58) | F2RCNR1TMEM97EPHX2EPHX1 | |
| SCHEMBL12719997 | 0.81 | F2R (0.46) | F2RCNR1TMEM97EPHX2EPHX1 | |
| SCHEMBL643046 | 0.81 | LIPE (0.49) | F2RCNR1TMEM97EPHX2 | |
| SCHEMBL641261 | 0.81 | F2R (0.69) | F2RCNR1TMEM97EPHX2 | |
| SCHEMBL642375 | 0.80 | F2R (0.56) | F2RCNR1TMEM97EPHX2EPHX1 | |
| SCHEMBL642019 | 0.80 | F2R (0.51) | F2RCNR1TMEM97EPHX2 | |
| SCHEMBL642101 | 0.80 | F2R (0.54) | F2RCNR1TMEM97EPHX2EPHX1 | |
| SCHEMBL1052035 | 0.79 | F2R (0.50) | F2RCNR1TMEM97EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214788-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214788-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-23 | — | — | US | disclosed |
| US-8119663-B2 | Heteroaryl-substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8119663-B2 | Heteroaryl-substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8119663-B2 | Heteroaryl-substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| WO-2009068214-A2 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | VHL, PIGO, PLIN3 | F2R 698/4885CNR1 454/4885TMEM97 1110/4885 |
| US-20120214788-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | VHL, PIGO, PLIN3 | F2R 698/4885CNR1 454/4885TMEM97 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.